Zinc Gluconate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Zinc Gluconate: From Unrecorded Original Indication to Anemia of Prematurity
One-Sentence Summary
This evidence pack does not record Zinc gluconate’s original approved indication or mechanism of action (both flagged as data gaps). The TxGNN model predicts a possible signal for Anemia of Prematurity, but this is currently a pure model prediction (Evidence Level L5) — 0 clinical trials and 0 publications were found addressing this specific drug-indication pair.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Anemia of Prematurity |
| TxGNN Prediction Score | 99.94% (model rank 584) |
| Evidence Level | L5 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Original Indication is omitted from this table — it is not recorded anywhere in the evidence pack (original_indications is empty).
Why is This Prediction Reasonable?
Detailed mechanism of action data for zinc gluconate is not available in this evidence pack (flagged as a High-severity data gap, DG002), and no original indication is on record either. This significantly limits how confidently the biological plausibility of the prediction can be assessed.
Based on the model’s own rationale, the proposed link rests on a general pharmacological property of zinc rather than on drug-specific evidence: zinc is known to interact with iron and copper metabolism, which could theoretically influence erythropoiesis (red blood cell production) — a pathway relevant to anemia. However, this is a class-level, theoretical mechanism, not something demonstrated for zinc gluconate specifically in the context of prematurity-related anemia.
No clinical trial or published study in this evidence pack directly tests zinc gluconate for anemia of prematurity. The prediction should be read as a hypothesis generated purely from knowledge-graph associations, not as a signal grounded in observed data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Zinc gluconate currently has no SAHPRA registrations on record and is not marketed in South Africa according to this evidence pack (0 licenses).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: this evidence pack flags a Blocking data gap (DG001) — TFDA/PI warnings and contraindications have not yet been retrieved — which by itself prevents this candidate from entering a safety pre-assessment (S1), independent of the efficacy evidence gap above.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for anemia of prematurity is supported only by a model score (Evidence Level L5) with no corroborating clinical trials or literature, and a separate Blocking data gap on safety labelling independently prevents progression to initial safety evaluation.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (warnings/contraindications) — currently Blocking (DG001)
- Mechanism of action data from DrugBank — currently High-severity gap (DG002)
- Confirmation of zinc gluconate’s original indication(s), which are not on record in this pack
- Targeted preclinical or clinical evidence testing zinc gluconate specifically in anemia of prematurity, since the current rationale is a general zinc–iron/copper interaction hypothesis rather than drug-specific data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.